Harvard Apparatus Regenerative Technology appoints Blaine McKee to the Board of Directors

– USA, MA – Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced the appointment of Blaine McKee, Ph.D., Senior Vice President and Head of Transactions at Shire plc, to HART’s Board of Directors. Dr. McKee has also been named to the Board’s Audit Committee, bringing HART back into compliance with the Nasdaq Capital Market’s requirement for audit committee composition.

Dr. McKee is a broadly skilled senior executive with over 20 years leadership experience in global biotechnology business development. Dr. McKee joined Shire in 2014 to lead its business development function. He was previously EVP and Chief Business Officer at 480 Biomedical, following 15 years at Genzyme Corporation, where he served as SVP of Strategic Development, leading global business development for the Organ Transplant, Oncology and Multiple Sclerosis business units. Dr. McKee successfully grew the oncology business at Genzyme from an early-stage research operation to a competitive and sustainable oncology and solid organ transplantation franchise, with global revenues of approximately $700M in 2011.

With extensive background in science, finance and strategy, Dr. McKee will help guide HART’s development activities including its current focus on completing an Investigative New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate human clinical trials for HART’s newly developed Cellframe™ technology for organ implants. Key large-animal data for HART’s Cellframe technology was first announced in November 2015. HART is now anticipating a read out of additional large-animal data in early May, resulting from its research collaboration with Mayo Clinic. These data are expected to confirm the regeneration seen in November and support the IND filing and orphan drug submission.

Dr. McKee said, “I am very excited to be working with the HART team. I look forward to supporting their efforts in bringing novel regenerated organ implant solutions to patients, generally with life-threatening conditions, who have few if any options other than radical surgeries, often with severe ongoing complications and quality of life impact.”

HART’s CEO, Jim McGorry, commented, “We are extremely pleased to bring Blaine and his extensive biotechnology industry expertise to HART’s Board. He possesses significant scientific depth and strategic planning acumen that should complement and strengthen our Board in meaningful ways.”

Dr. McKee earned a Ph.D. degree in organic chemistry from Massachusetts Institute of Technology, an MBA from MIT Sloan School of Management, and a Bachelor’s degree in chemistry from Colorado State University.

About Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology (HART) is developing bioengineered organ implants utilizing the recipient’s own stem cells to treat life-threatening conditions. HART has developed and begun testing a new technology platform to create organ implants to replace diseased or damaged portions of the esophagus, trachea or bronchus to restore function.

Harvard Apparatus Regenerative Technology, Inc. novel Cellframe technology platform utilizes new materials and methods of construction, and a different type and concentration of the patient’s own stem cells and certain other improvements to address the needs of affected patients. This new platform is currently being tested and developed further in a large-animal collaborative study with Mayo Clinic. HART is working to refine its new platform and to develop compelling data to pursue its goals of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in late 2016 to initiate clinical trials for one of its three product candidates and compassionate use implantation surgeries.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>